[Effect of hyperandrogenism on pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer]
- PMID: 37032154
- DOI: 10.3760/cma.j.cn112137-20220926-02032
[Effect of hyperandrogenism on pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer]
Abstract
Objective: To explore the effects of hyperandrogenism (HA) on pregnancy outcomes in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). Methods: A retrospective study was conducted on infertile women with PCOS undergoing IVF/ICSI-ET from January 2017 to June 2021 in our center. Patients were divided into HA group and NON-HA group according to the levels of testosterone. Propensity score matching (PSM) was used to balance the influence of female age and IVF/ICSI-ET for patients with gonadotropin-releasing hormone (GnRH)antagonist protocol and GnRH agonist protocol, separately. After the PSM procedure, 191 cases in HA group and 382 cases in NON-HA group, were included. Hormone levels and pregnancy outcomes were compared in the two groups. Results: The female age was comparable in two groups [HA: (29.6±3.7) vs NON-HA: (29.5±3.6), P=0.665]. The basal luteinizing hormone [(10.82±6.73) vs (7.76±5.30) IU/L], testosterone [(3.27±0.97) vs (1.60±0.59) nmol/L], free androgen index (7.13 vs 2.77), anti-mullerian hormone [(11.37±5.74) vs (9.67±4.67) ng/ml], fasting glucose [(5.18±0.49) vs (5.06±0.42) mmol/L], 1h glucose [(9.34±2.42) vs (7.99±2.21) nmol/L], 2 h glucose [(7.66±2.17) vs (6.64±1.84) nmol/L], 2 h insulin [(129.81±145.49) vs (97.51±86.92) mU/L], total cholesterol [(5.35±0.89) vs (4.92±0.92) mmol/L], triglycerides [(1.55±1.28) vs (1.33±0.77) mmol/L], and low density lipoprotein cholesterol levels [(3.38±0.66) vs (3.14±0.71) mmol/L] were significantly higher in HA group, compared with NON-HA group (P<0.05). The initiated gonadotropin dose was higher in HA group than that in NON-HA group [(126.96±33.65) vs (137.60±38.12) U, P=0.001], but moderate-severe ovarian hyperstimulation syndrome (OHSS) rate was similar in two groups (P>0.05). The rates of implantation, clinical pregnancy, miscarriage, and live birth were comparable between the two groups (P>0.05). Also, in the subgroups, the rates of implantation, clinical pregnancy, live birth, and miscarriage were similar in HA group and NON-HA group. Conclusions: The risks of hormonal abnormality and glucose-lipid metabolic disorder were higher in PCOS women with HA, whereas satisfactory pregnancy outcomes could be achieved under proper ovarian stimulation undergoing IVF/ICSI-ET.
目的: 分析高雄激素血症多囊卵巢综合征(PCOS)患者行体外受精/卵细胞浆内单精子注射-胚胎移植(IVF/ICSI-ET)助孕的临床结局。 方法: 本研究为横断面研究,选择2017年1月至2021年6月在中山大学孙逸仙纪念医院生殖中心行IVF/ICSI-ET助孕的PCOS患者的临床资料,共573例,将患者分为高雄激素血症组(HA组,191例)和非高雄激素血症组(NON-HA组,382例),按照拮抗剂方案和黄体期长方案分别采用1∶2倾向性评分匹配,用于平衡2组患者的女方年龄和受精方式,匹配后HA组191例,NON-HA组382例,比较2组患者的激素水平及妊娠结局等指标。 结果: HA组和NON-HA组患者的年龄分别为(29.6±3.7)和(29.5±3.6)岁(P=0.665)。与NON-HA组比较,HA组基础黄体生成素[(10.82±6.73)比(7.76±5.30)IU/L]、睾酮[(3.27±0.97)比(1.60±0.59)nmol/L]、游离雄激素指数(7.13比2.77)、抗苗勒管激素[(11.37±5.74)比(9.67±4.67)ng/ml]、0 h葡萄糖[(5.18±0.49)比(5.06±0.42)mmol/L]、1 h葡萄糖[(9.34±2.42)比(7.99±2.21)nmol/L]、2 h葡萄糖[(7.66±2.17)比(6.64±1.84)nmol/L]、2 h胰岛素[(129.81±145.49)比(97.51±86.92)mU/L]、总胆固醇[(5.35±0.89)比(4.92±0.92)mmol/L]、甘油三酯[(1.55±1.28)比(1.33±0.77)mmol/L]、低密度脂蛋白胆固醇[(3.38±0.66)比(3.14±0.71)mmol/L]均偏高,差异均有统计学意义(均P<0.05)。HA组促性腺激素启动剂量低于NON-HA组[(126.96±33.65)比(137.60±38.12)U](P=0.001),而2组患者中重度卵巢过度刺激综合征(OHSS)发生率差异无统计学意义(P>0.05)。同时,2组患者着床率、临床妊娠率、活产率和流产率差异均无统计学意义(均P>0.05)。 结论: 高雄激素血症的PCOS患者生殖内分泌激素紊乱和糖脂代谢异常风险升高,在行IVF/ICSI助孕时,合适的促排卵治疗能获得与雄激素水平正常者相似的妊娠结局。.
Similar articles
-
Hyperandrogenism increases late spontaneous miscarriage in polycystic ovary syndrome women due to cervical insufficiency? A propensity-score matching study.BMC Pregnancy Childbirth. 2025 Feb 28;25(1):222. doi: 10.1186/s12884-025-07342-4. BMC Pregnancy Childbirth. 2025. PMID: 40022012 Free PMC article.
-
Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.Curr Med Sci. 2019 Jun;39(3):431-436. doi: 10.1007/s11596-019-2055-x. Epub 2019 Jun 17. Curr Med Sci. 2019. PMID: 31209815
-
Body mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome.Reprod Biol Endocrinol. 2018 Nov 19;16(1):119. doi: 10.1186/s12958-018-0438-7. Reprod Biol Endocrinol. 2018. PMID: 30454060 Free PMC article.
-
Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.Sci Rep. 2022 Mar 15;12(1):4456. doi: 10.1038/s41598-022-08400-z. Sci Rep. 2022. PMID: 35292717 Free PMC article.
-
Association between hyperandrogenism and adverse pregnancy outcomes in patients with different polycystic ovary syndrome phenotypes undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis.Gynecol Endocrinol. 2021 Aug;37(8):694-701. doi: 10.1080/09513590.2021.1897096. Epub 2021 Mar 11. Gynecol Endocrinol. 2021. PMID: 33703999
Cited by
-
Impact of dehydroepiandrosterone sulfate and free androgen index on pregnancy and neonatal outcomes in PCOS patients.Reprod Biol Endocrinol. 2024 Apr 16;22(1):43. doi: 10.1186/s12958-024-01212-y. Reprod Biol Endocrinol. 2024. PMID: 38627777 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous